Remove Compounding Remove FDA Remove Labelling Remove Process Improvement
article thumbnail

A Proposal for a Comprehensive Quality Overall Summary

ISPE

Application of this innovative approach will quickly orient regulators to the content of Module 3, “present product quality benefit-risk considerations, summarize the pharmaceutical development, present an overall understanding of the product quality,” 1 and facilitate continuous improvement.

article thumbnail

A Proposal for a Comprehensive Quality Overall Summary

ISPE

Application of this innovative approach will quickly orient regulators to the content of Module 3, “present product quality benefit-risk considerations, summarize the pharmaceutical development, present an overall understanding of the product quality,” 1 and facilitate continuous improvement.

article thumbnail

Regulatory Landscape for Raw Materials: CMC Considerations

ISPE

With shortages, regulatory complexity is compounded due to differences in submission and data requirements from various regulatory agencies. Although they have been historically overlooked as a key element, raw materials are a critical component at every stage of the drug manufacturing processes. Burke, PhD. 1 September 2022.